Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1867-1873

  Roila, Fausto ^a   Rolski, J ^b   Ramlau, R ^c   Dediu, M ^d   Russo, M W ^e   Bandekar, R R ^e   Grunberg, S M ^f  

^a S MARIA HOSPITAL   (Italy)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c Oncology Department   (Poland)

^d Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

^e GLAXOSMITHKLINE   (United States)

^f FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Antiemetics; Antineoplastic combined chemotherapy protocols; Combination; Drug Therapy; Nausea; Neurokinin 1; Vomiting

Indexed keywords

APREPITANT; CASOPITANT; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; NAVELBINE; ONDANSETRON; PLACEBO;

ADULT; AGED; ARTICLE; ASTHENIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HICCUP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; ONDANSETRON; PIPERAZINES; PIPERIDINES; RECEPTORS, NEUROKININ-1; VOMITING;

EID: 71049145217     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp194     Document Type: Article

References (14)

1. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006; 24: 2932-2947.
2. Roila F, Hesketh PJ, Herrstedt J. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-28.
3. Multinational Association of Supportive Care in Cancer. Antiemetic guidelines. http://www.mascc.org/content/127.html (20 January 2009, date last accessed).
4. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-4119.
5. de Wit R, Herrstedt J, Rapoport B et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003; 21: 4105-4111.
6. Warr DG, Grunberg SM, Gralla RJ et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005; 41: 1278-1285.
7. Schmoll HJ, Aapro MS, Poli-Bigelli et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006; 17: 1000-1006.
8. Gagnon RC, King AG. Co-administration of ondansetron and casopitant mesylate, a novel NK-1 receptor antagonist, results in augmented anti-emetic activity in the ferret. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I 2006; 24 (18S) (Suppl): 18608.
9. King AG. Complete rescue from established emesis by the NK-1 receptor antagonist, casopitant mesylate, in cisplatin-induced delayed emesis in the ferret. J Clin Oncol 2006 2006 ASCO Annual Meeting Proceedings Part I 2006; 24 (18S) (Suppl): 18601.
10. Chung F, Singla N, Singla S et al. Casopitant for preventing postoperative vomiting in patients receiving opioids: Pooled data analysis. Anesthesiology 2006; 105: A206.
11. Emend (Aprepitant) [Package Insert]. Whitehouse Station, NJ: Merck & Co., Inc 2006.
12. Grunberg S, Clark-Snow RA, Koeller J. Chemotherapy-induced nausea and vomiting: Contemporary approaches to optimal management. Support Care Cancer 2009; in press.
13. Williams PL, Armitage P, Colton T (eds). Encyclopedia of Biostatistics. Trend Tests for Counts and Proportions, 6th edition. Chichester, UK: Wiley 1998; 4573-4584.
14. Herrstedt J, Grunberg SM, Rolski J et al. Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC). J Clin Oncol 2008; 26 (Suppl): (Abstr 9549).